Treatment withdrawal · people with drug‐resistant focal epilepsy
Topiramate leads to higher treatment withdrawal compared with placebo (high certainty).
1 finding from 1 review
Adverse events ‐ weight loss · people with drug‐resistant focal epilepsy
Topiramate may leads to higher adverse effects ‐ weight loss/decrease compared with placebo (low certainty).
1 finding from 1 review
Paraesthesia · people with drug‐resistant focal epilepsy
Topiramate probably leads to higher adverse effects ‐ paraesthesia compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects ‐ 'thinking abnormally' · people with drug‐resistant focal epilepsy
Topiramate leads to higher adverse effects ‐ 'thinking abnormally' compared with placebo (high certainty).
1 finding from 1 review
Adverse effects ‐ difficulty with concentration/concentration impaired/concentration‐attention difficulties · people with drug‐resistant focal epilepsy
Topiramate probably leads to higher adverse effects ‐ difficulty with concentration/concentration… compared with placebo (moderate certainty).
1 finding from 1 review
Annual rate of change in % predicted FEV1 All participants · adults and children with cystic fibrosis
1 finding from 1 review
Annual rate of change in % predicted FEV1 Subgroup: under 13 years of age · adults and children with cystic fibrosis
1 finding from 1 review
Annual rate of change in % predicted FEV1 Subgroup: over 13 years of age · adults and children with cystic fibrosis
1 finding from 1 review
Annual rate of change in % predicted FVC All participants · adults and children with cystic fibrosis
1 finding from 1 review
Annual rate of change in % predicted FVC Subgroup: Under 13 years of age · adults and children with cystic fibrosis
1 finding from 1 review
Annual rate of change in % predicted FVC Subgroup: Over 13 years of age · adults and children with cystic fibrosis
1 finding from 1 review
Transmission‐related outcomes: hospitalization ‐ Number or proportion of hospital admissions · adults and children with cystic fibrosis
Summary of findings: non‐steroidal anti‐inflammatory drugs showed no clear difference in proportion with at least 1 hospital admission compared with placebo (moderate certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Tiagabine leads to higher 50% or greater reduction in seizure frequency (Intention‐to‐treat… compared with placebo control (high certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Tiagabine probably leads to higher treatment withdrawal compared with placebo control (moderate certainty).
1 finding from 1 review
Dizziness · people with drug‐resistant focal epilepsy
Tiagabine probably leads to higher dizziness compared with placebo control (moderate certainty).
1 finding from 1 review
Fatigue · people with drug‐resistant focal epilepsy
Tiagabine showed no clear difference in fatigue compared with placebo control (moderate certainty).
1 finding from 1 review
Nausea · people with drug‐resistant focal epilepsy
Tiagabine showed no clear difference in nausea compared with placebo control (low certainty).
1 finding from 1 review
Somnolence · people with drug‐resistant focal epilepsy
Tiagabine showed no clear difference in somnolence compared with placebo control (moderate certainty).
1 finding from 1 review
Tremor · people with drug‐resistant focal epilepsy
Tiagabine showed no clear difference in tremor compared with placebo control (low certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) All participants Range of · adults and children with newly onset partial or generalised epilepsy
Carbamazepine showed no clear difference in time to treatment failure (any reason related to treatment)All… compared with phenytoin (time to treatment failure) (moderate certainty).
1 finding from 1 review